Free access supported by contributions and sponsoring — share your knowledge or support us financially
Search / Compare / Validate Lab equipment & Methods

Market Availability & Pricing

Stata/SE is an officially marketed data analysis software product from StataCorp. Pricing varies based on license type and duration, with a single-user annual license available for around $925 and a perpetual license with maintenance costing approximately $4,625. StataCorp offers Stata/SE through authorized distributors.

Need Operating Instructions, SDS, or distributor details? Just ask our AI Agent.

Is this product still available?

Get pricing insights and sourcing options

The spelling variants listed below correspond to different ways the product may be referred to in scientific literature.
These variants have been automatically detected by our extraction engine, which groups similar formulations based on semantic similarity.

Product FAQ

714 protocols using «stata se»

1

Usability Evaluation of a School Nurse Intervention

2025
Qualitative notes from the cognitive walkthroughs were typed, deidentified, and reviewed weekly by two members of the research team (EN and CAM). Usability issues captured from the notes related to both the intervention generally and its specific components, as elicited by the scenarios. The reviewers tallied the number of participants who identified the same issue, adding new usability issues as needed as cognitive walkthroughs continued. Once completed, the reviewers organized the usability issues by type using 13 categories in the UCD literature (step 4) [30 (link)]. Two investigators assigned a priority score (1=not important, 2=somewhat important, and 3=very important) for additional adaptations needed to generate a workable intervention. Priority scores were based on the perceived likely impact on future end users, the likelihood that this would be experienced by users, and how critical it is for the success of SPACE [39 (link)]. Independent scores were then averaged and sorted from highest to lowest priority. We examined the correlation between the priority rating and the percentage of school nurse participants identifying the issue using Spearman’s correlation. The usability issues and priority rankings were shared with the design team to determine any additional refinements to SPACE.
Quantitative data included case scenario ratings and IUS scores. Ratings for each case scenario and the IUS scores were averaged across participants and presented as a mean and SD. We explored differences in IUS scores using one-way ANOVA among groups with differing characteristics perceived to influence school nurse workload and skill level, including school nursing experience (<10 years vs ≥10 years), caseload (<750, 750-1000, or 1001-1500 students), number of schools covered (1, 2, and more than 2), and students with type 1 diabetes in the past 5 years (<5, 5-10, or >10 students) [44 (link)]. A P value of <.05 was considered significant. All statistical analyses were completed using StataSE (version 17; StataCorp).
+ Open protocol
+ Expand Check if the same lab product or an alternative is used in the 5 most similar protocols
2

Cardio-Oncology Consultation Adherence

2025
The primary endpoint was adherence to cardio-oncology consultation. We tested the null hypothesis that the proportion of adherent patients is no more than 70% using an exact Binomial test at 5% nominal significance level with 3.5% as actual significance level. Thus, if the number of adherent patients was greater or equal to 18 patients, then we reject the null hypothesis and declare the study as feasible. Secondary endpoints included the rate of CV medication intervention by cardio-oncology and patient-reported intervention perspectives by survey. Data was summarized using descriptive statistics, including n (%), median (interquartile rage [IQR]), or mean (±standard deviation) where indicated. No participants were excluded from analysis. Analyses were performed using StataSE (version 17.0; StataCorp LLC) statistical software.
+ Open protocol
+ Expand Check if the same lab product or an alternative is used in the 5 most similar protocols
3

COVID-19 Impact on Medical Procedure Volumes

2025
Recovery, defined as per cent return in 2021 to 2019 baseline from 2020 volumes at the initial phase of the pandemic, was calculated as: 100%×{1–[(March 2019 volume–April 2021 volume)/(March 2019 volume–April 2020 volume)]}. The per cent change in procedure volumes from March 2019 to April 2020 was calculated as: 100%×[(April 2020 volume–March 2019 volume)/(March 2019 volume)] and analogously for March 2019 to April 2021. The median per cent change was calculated for each testing modality and compared between Asia and the RoW, among the four Asian subregions, and among Asian countries of different income levels. Wilcoxon rank sum and Kruskal-Wallis tests were used to compare differences in continuous variables, while differences in survey response distributions were compared by Fisher’s exact tests. Statistical analysis was performed using Stata/SE version 15.1 (StataCorp) and Microsoft Excel (Microsoft, Redmond, Washington, USA). A two-tailed p<0.05 was considered statistically significant. Maps were created using the rnaturalearth and tmap packages in R V.4.3.3 (R Development Core Team).
+ Open protocol
+ Expand Check if the same lab product or an alternative is used in the 5 most similar protocols
4

Surgical Adverse Events and Outcomes

2025
For the statistical analyses, Stata SE (StataCorp LLC, College Station, TX, USA) v18.0 for Mac was used. We mostly employed descriptive statistics, reporting results as mean (standard deviation; SD) or count (percent). Probability values of <0.05 were considered statistically significant. A uni- and multivariable logistic regression model was used for analysis of the surgical AEs and outcomes at discharge and after three and 12 months and calculating odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for the following potentially confounding variables: age, smoking status, disease type, CCI, and ASA grade after ruling out collinearity. Sensitivity analyses were performed with slightly different stratifications of the CFI score (e.g., excluding “vulnerable” patients in the frail group).
+ Open protocol
+ Expand Check if the same lab product or an alternative is used in the 5 most similar protocols
5

Postoperative Care Delivery Survey in NWS

2025
In addition to the interviews, a survey (online supplemental appendix 2) was distributed to hospital clinicians in NWS between April and May 2022 via hospital administrators and non-governmental organisation (NGO) leadership. The aims were twofold: (1) to gain a broader understanding of postoperative care delivery past interviewees’ experiences and (2) to ensure broad representation of clinician and administrator perspectives given the high level of fragmentation of the healthcare system in NWS. The survey consisted of 50 questions divided into seven sections: demographics, charting and discharge processes, clinical documentation, the role of NGOs, hospital administration, postoperative complications and follow-up care. It was distributed to hospital administrators and NGO leadership in both Idlib and Aleppo (hospital information can be found in online supplemental appendix 3), but respondents were asked to focus on their experiences in Idlib hospitals. Administrators and NGO leadership were asked to distribute the survey to all employees engaging in clinical work in their facilities. After 20 responses, the survey was edited for further clarity, and the initial responses were excluded from final analysis. As with the interview data, the de-identified survey data were provided to the research team. Responses were analysed using Stata/SE (V.18.0, StataCorp LLC, College Station, Texas); summary statistics were used to describe the cohort and their responses.
+ Open protocol
+ Expand Check if the same lab product or an alternative is used in the 5 most similar protocols

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!

🧪 Need help with an experiment or choosing lab equipment?
I search the PubCompare platform for you—tapping into 40+ million protocols to bring you relevant answers from scientific literature and vendor data.
1. Find protocols
2. Find best products for an experiment
3. Validate product use from papers
4. Check Product Compatibility
5. Ask a technical question
Want to copy this response? Upgrade to Premium to unlock copy/paste and export options.